Understanding the Alpha/Beta Ratio: A Key Concept for FRCR Part 1 Radiobiology
The alpha/beta ratio is one of the most important concepts in radiobiology and frequently tested in FRCR Part 1. Learn what it means, why it matters, and how to apply it clinically.
What is the Alpha/Beta Ratio?
The alpha/beta (α/β) ratio is a fundamental concept in radiation oncology that describes how different tissues respond to radiation doses. If you're preparing for the FRCR Part 1 exam, understanding this ratio is essential—it appears in multiple questions and underpins many clinical decisions in radiotherapy.
In simple terms, the α/β ratio represents the dose (in Gray) at which the linear (α) and quadratic (β) components of cell killing contribute equally to radiation damage.
The Linear-Quadratic Model
The α/β ratio is derived from the linear-quadratic (LQ) model, which describes cell survival following radiation exposure:
Surviving Fraction = e-(αD + βD²)
Where:
- D = radiation dose
- α = coefficient for linear (single-hit) cell killing
- β = coefficient for quadratic (two-hit) cell killing
The α component represents irreparable lethal damage (like double-strand breaks from a single radiation track), while the β component represents damage from the accumulation of sublethal events.
Low vs High Alpha/Beta Ratios
Low α/β Ratio (1-5 Gy): Late-Responding Tissues
Tissues with low α/β ratios include:
- Spinal cord (~2 Gy)
- Brain (~2 Gy)
- Kidney (~3 Gy)
- Lung (~3 Gy)
- Prostate cancer (~1.5-3 Gy)
These tissues are more sensitive to larger doses per fraction and show greater sparing with smaller fractions. This is why late-responding normal tissues benefit from conventional fractionation.
High α/β Ratio (8-10+ Gy): Early-Responding Tissues
Tissues with high α/β ratios include:
- Skin (~10 Gy)
- Mucosa (~10 Gy)
- Bone marrow (~10 Gy)
- Most rapidly proliferating tumours (~10 Gy)
These tissues respond similarly regardless of fractionation—they're sensitive to total dose rather than dose per fraction.
Clinical Applications
Conventional Fractionation (1.8-2 Gy/day)
Traditional fractionation schemes were designed to spare late-responding normal tissues (low α/β) while maintaining tumour kill (high α/β). The small doses per fraction exploit the difference between tumour and normal tissue responses.
Hypofractionation (>2 Gy/day)
Hypofractionation delivers fewer, larger fractions. It's particularly effective for tumours with low α/β ratios:
- Prostate cancer (α/β ≈ 1.5-3 Gy): Responds well to larger fractions
- Breast cancer (α/β ≈ 4 Gy): UK trials (START A, START B) showed equivalent outcomes with shorter courses
SBRT/SRS (Very High Doses per Fraction)
Stereotactic treatments use very large doses (often 7-20 Gy per fraction). The radiobiological advantage comes from precise targeting that minimizes normal tissue exposure.
Biologically Effective Dose (BED)
The BED allows comparison of different fractionation schemes:
BED = D × (1 + d/(α/β))
Where:
- D = total dose
- d = dose per fraction
- α/β = ratio for the tissue of interest
This formula is essential for comparing treatment regimens and appears frequently in FRCR exams.
Key Points for FRCR Part 1
- Late-responding tissues have LOW α/β ratios (1-5 Gy)
- Early-responding tissues and most tumours have HIGH α/β ratios (8-10 Gy)
- Prostate cancer is an exception with a LOW α/β ratio (~1.5 Gy)
- Conventional fractionation spares late-responding tissues
- Hypofractionation can improve therapeutic ratio for low α/β tumours
- BED calculations allow comparison of different fractionation schemes
Practice Questions
Test your understanding with our comprehensive radiobiology question bank at PassOncology. We cover the α/β ratio, the 5 Rs of radiobiology, cell survival curves, and all other key concepts for FRCR Part 1.
Enjoyed this article?
Share it with a colleague preparing for their FRCR.